An Open-label Study of the Effect of First-line Treatment With Avastin+Xelox, Followed by Avastin+Tarceva, on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Phase 2
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Colorectal Cancer
Both
Colorectal Cancer
Trial Information
An Open-label Study of the Effect of First-line Treatment With Avastin+Xelox, Followed by Avastin+Tarceva, on Progression-free Survival in Patients With Metastatic Colorectal Cancer
Inclusion Criteria:
- adult patients, >=18 years of age;
- adenocarcinoma of colon or rectum, with metastatic disease;
- >=1 measurable lesion.
Exclusion Criteria:
- previous treatment with Avastin or Tarceva;
- previous systemic treatment for advanced or metastatic disease;
- adjuvant treatment for non-metastatic disease in past 6 months.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Progression-free survival\n
Outcome Time Frame:
From study start up to approximately 4 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Chair
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Spain: Ministry of Health and Consumption
Study ID:
ML19875
NCT ID:
NCT01135498
Start Date:
November 2006
Completion Date:
April 2010
Related Keywords:
- Colorectal Cancer
- Colorectal Neoplasms
Name | Location |
|---|
